Lactobacillus gasseri (probiotic): benefits, dosage, contraindications
Family or group:
Probiotics
Indications
Scoring methodology
EFSA approval.
Weight control ✪✪✪✪✪
Consumption of Lactobacillus gasseri leads to a reduction in abdominal adiposity. A randomized, double-blind, placebo-controlled trial of a Japanese scientific study conducted in 2010 on 87 healthy adults with high abdominal adiposity (overweight) evaluated the effects of the strain L. gasseri SBT2055 on abdominal adiposity and body weight. The results show that the group treated with a course of L. gasseri SBT2055 for 12 weeks lost 4.6% abdominal fat and 3.3% subcutaneous fat compared with the control group. Likewise, their body weight, waist circumference and BMI decreased by 1.4% (1.1 kg), 1.8% (1.7 cm) and 1.5% (0.4 kg/m2), respectively. Another randomized, double-blind, placebo-controlled trial conducted on 90 volunteers aged 20 to 75 observed a significant decrease in visceral adiposity in obese adults. These studies showed the beneficial effect of supplementation with L. gasseri in significantly reducing abdominal and visceral adiposity in overweight or obese humans. In a 2015 clinical study published in the journal Lipids in Health and Disease, more was learned about the mechanism of this bacterial strain. In this study, Japanese researchers demonstrated that the strain L. gasseri SBT2055 suppresses the release of fatty acids from a fat emulsion by increasing the size of micelle particles. This increase in size is known to hinder the action of the enzyme involved in the absorption of dietary lipids, pancreatic lipase. Moreover, the same research team observed in humans that consumption of fermented milk with L. gasseri SBT2055 caused an increase in fecal fat excretion. This effect may be associated with the inhibition of fat breakdown observed in vitro. According to this study, L. gasseri therefore clearly limits fat absorption at the intestinal level.
Posologie
Oral route
Lactobacillus gasseri SBT2055 suppresses fatty acid release through enlargement of fat emulsion size in vitro and promotes fecal fat excretion in healthy Japanese subjects
Effect of Lactobacillus gasseri BNR17 on Overweight and Obese Adults: A Randomized, Double-Blind Clinical Trial
Lactobacillus gasseri BNR17 Supplementation Reduces Visceral Fat Accumulation and Waist Circumference in Obese Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with a tendency toward obesity in a randomized controlled trial
Helicobacter pylori infection ✪✪✪✪✪
Meta-analyses of clinical research show that taking lactobacilli can improve H. pylori eradication rates by 1.14 to 1.24 times when combined with triple therapy, consisting of a proton pump inhibitor (PPI), clarithromycin, and amoxicillin.rnrnThe specific species of lactobacilli that have shown benefits in treating H. pylori infections include L. gasseri one billion colony-forming units (CFU) twice daily for 4 to 8 weeks, starting 3 weeks before the triple therapy, a freeze-dried, inactivated culture of L. acidophilus containing L. acidophilus L.B 5 billion heat-killed cells, three times daily for 10 days, and a mixture of two strains of L. reuteri (DSM 17938 and ATCC PTA 6475; e.g., Gastrus, BioGaia AB) 100 million CFU of each strain once daily for about 14 weeks, before and after the triple therapy.rnrn
Posologie
Oral route
2 IU
Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection
Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy
The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis
Endometriosis ✪✪✪✪✪
According to a Cytotechnology 2011 publication, oral intake of L. gasseri OLL2809 effectively reduces menstrual pain and dysmenorrhea associated with endometriosis compared with placebo, suggesting that L. gasseri OLL2809 is useful for improving the quality of life of patients with endometriosis. L. gasseri OLL2809 could play a role in pain relief through increased generation of IL-12, known to induce proliferation and cytotoxicity of NK cells. Previous research has suggested that endometriotic cells are natural target cells of NK cells, and that impaired clearance of ectopic endometrium by NK cells in the peritoneal cavity contributes to the development of the disease.
Posologie
Orally
Properties
Antibacterial
Some research suggests that lactobacilli are able to reduce the adherence of pathogenic bacteria to the colonic mucosa and reduce bacterial translocation, which could make them useful in preventing infections and in treating diseases such as Crohn's disease. The antimicrobial activity, in vitro, of L. gasseri LA39 has been demonstrated against various pathogens: Listeria monocytogenes, Bacillus cereus and Staphylococcus aureus. Like all lactic acid bacteria, L. gasseri also produces organic acids. Moreover, it metabolizes glucose into lactic acid. This secretion of lactic acid will cause an acidification capable of inhibiting pathogenic bacteria. Furthermore, it has been observed in vitro, the ability of the strain Lactobacillus gasseri, to inhibit the adhesion and colonization of Escherichia coli at the intestinal mucosal level.
Usages associés
Anti-inflammatory
Lactobacillus gasseri helps fight inflammation. More specifically, data suggest that Lactobacillus gasseri enables in vitro and in vivo significant reductions in the plasma release of inflammation mediators such as pro-inflammatory cytokines. At the same time, this probiotic induces an increase in cytokines that regulate inflammation. Furthermore, a randomized double-blind placebo-controlled study was conducted on 32 healthy elderly subjects for three weeks, taking twice daily a probiotic blend (Lactobacillus gasseri KS-13, Bifidobacterium longum MM2, B. bifidum G9-1). The researchers evaluated the effect of this supplementation on various parameters: circulating CD4+ lymphocyte counts, cytokine production, and the shift of the gut microbiota toward a healthy bacterial population. Intake of this high-concentration probiotic formulation preserved CD4+ lymphocytes and reduced the profile of inflammatory cytokines. The hypothesis proposed by the researchers is a normalization of the microbial communities, which more closely resembled those reported in younger healthy populations. More broadly, numerous studies have clearly established that Lactobacillus gasseri has a natural resistance, able to survive gastric acidity. It would therefore better protect against inflammation encountered in cases of gastritis, stomach ulcers, including the ulcer associated with an Helicobacter pylori infection and irritable bowel syndrome.
Usages associés
Immunomodulator
Some researchers believe that lactobacilli and other probiotics may have immunomodulatory effects. Lactobacilli appear to modulate non-specific cellular and humoral immunity, probably by stimulating the activity of lymphocytes and macrophages and by modulating cytokine production by mononuclear cells. A double-blind, placebo-controlled clinical study of two strains of lactobacilli, L. gasseri CECT5714 and L. coryniformis CECT5711, was conducted in 50 healthy adults, compared with consumption of regular yogurt. The results show that consumption of the two strains, like the yogurt, produces a significant increase in phagocytic cells (monocytes and neutrophils) after two weeks (and it persists at four weeks) with little difference between the two groups. However, a significant difference was observed in the increase of natural killer (NK) cells in favor of the two new strains; the effect being more pronounced at two weeks than at four.
Metabolic
L. gasseri has been associated with a tendency toward weight loss in lean animals in three studies and four comparisons including 48 pigs and rats. In obese animals and humans, three studies and three comparisons including 87 humans and rats found an anti-obesity effect. This effect was consistent between humans and animals. Two strains of L. gasseri (SBT2055 and BNR17) have a significant anti-obesity effect in individual studies.
Usages associés
Safe dosage
Adult: 2 IU
The microorganism content ranges from 2 to 12 billion CFU (Colony-Forming Units)
